BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice
AuthorsKhroyan, Taline V.
Polgar, Willma E.
Husbands, Stephen M.
MetadataShow full item record
AbstractBackground and Purpose Buprenorphine is a potent analgesic with high affinity at μ, δ and κ and moderate affinity at nociceptin opioid (NOP) receptors. Nevertheless, NOP receptor activation modulates the in vivo activity of buprenorphine. Structure activity studies were conducted to design buprenorphine analogues with high affinity at each of these receptors and to characterize them in in vitro and in vivo assays. Experimental Approach Compounds were tested for binding affinity and functional activity using [35S]GTPγS binding at each receptor and a whole‐cell fluorescent assay at μ receptors. BU08073 was evaluated for antinociceptive agonist and antagonist activity and for its effects on anxiety in mice. Key Results BU08073 bound with high affinity to all opioid receptors. It had virtually no efficacy at δ, κ and NOP receptors, whereas at μ receptors, BU08073 has similar efficacy as buprenorphine in both functional assays. Alone, BU08073 has anxiogenic activity and produces very little antinociception. However, BU08073 blocks morphine and U50,488‐mediated antinociception. This blockade was not evident at 1 h post‐treatment, but is present at 6 h and remains for up to 3–6 days. Conclusions and Implications These studies provide structural requirements for synthesis of ‘universal’ opioid ligands. BU08073 had high affinity for all the opioid receptors, with moderate efficacy at μ receptors and reduced efficacy at NOP receptors, a profile suggesting potential analgesic activity. However, in vivo, BU08073 had long‐lasting antagonist activity, indicating that its pharmacokinetics determined both the time course of its effects and what receptor‐mediated effects were observed.
CitationKhroyan T, Wu J, Polgar W, Cami-Kobeci G, Fotaki N, Husbands S, Toll L (2015) 'BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice', British Journal of Pharmacology, 172 (2), pp.668-680.
PublisherJohn Wiley and Sons Inc.
JournalBritish Journal of Pharmacology
PubMed Central IDPMC4292977
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Yellow - can archive pre-print (ie pre-refereeing)
- Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
- Authors: Khroyan TV, Polgar WE, Jiang F, Zaveri NT, Toll L
- Issue date: 2009 Dec
- The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward.
- Authors: Khroyan TV, Polgar WE, Cami-Kobeci G, Husbands SM, Zaveri NT, Toll L
- Issue date: 2011 Mar
- Activities of mixed NOP and mu-opioid receptor ligands.
- Authors: Spagnolo B, Calo G, Polgar WE, Jiang F, Olsen CM, Berzetei-Gurske I, Khroyan TV, Husbands SM, Lewis JW, Toll L, Zaveri NT
- Issue date: 2008 Feb
- Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
- Authors: Mizoguchi H, Spaulding A, Leitermann R, Wu HE, Nagase H, Tseng LF
- Issue date: 2003 Jul
- Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
- Authors: Sukhtankar DD, Zaveri NT, Husbands SM, Ko MC
- Issue date: 2013 Jul